UHPLC‐Q‐TOF‐MS Identification of Intestinal Absorbable Components of Yindan Pinggan Capsule and Exploration of Its Anti‐NAFLD Mechanism Based on NF‐κB Signaling Regulation
Biomedical Chromatography · 2026-12 · 40 (12)
DOI: 10.1002/bmc.70650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 04.11.2026. Verfasst von Jinli Hou und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, NF-kappa B, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences.
Abstract (Originalsprache)
Yindan Pinggan capsule (YDPG) is a traditional Chinese formula for liver disorders, but its mechanism against nonalcoholic fatty liver disease (NAFLD) remains unclear. Here, UHPLC‐Q‐TOF‐MS was used to characterize YDPG's chemical profile, and the YDPG intestinal absorption solution (YDPGIAS) obtained via the everted gut sac model was analyzed to identify absorbable components. Network pharmacology, transcriptomic sequencing, molecular docking, and in vitro assays in oleic acid–induced BRL‐3A hepatocytes were integrated to predict targets and validate effects. A total of 164 compounds were identified from YDPG; 84 were detected in YDPGIAS, with 15 confirmed by reference standards. YDPGIAS significantly reduced lipid accumulation and lowered triglyceride, total cholesterol, LDL‐cholesterol, and HDL‐cholesterol levels. Integrated analysis identified the NF‐κB pathway as the core candidate mechanism, involving targets LYN, TNF, and IL1B, and key compounds including baicalin, ferulic acid, and gentiopicroside. Molecular docking predicted favorable binding affinities, and cellular experiments confirmed lipid‐lowering effects. These results demonstrate that YDPG ameliorates NAFLD through multicomponent, multitarget regulation of the NF‐κB‐mediated inflammatory pathway, providing a preliminary basis for further pharmacological and clinical investigation in NAFLD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, China.
- Modern Research Center for Traditional Chinese Medicine, the Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, Taiyuan, Shanxi, China.
- Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
- Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
ORCID-Profile: Jinli Hou, Jie Zhao, Huaqing Lai, Hongwei Wu
Förderung
- Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences
Zitieren
APA
Hou, J., Zhao, J., Yang, J., Lai, H., Jia, M., Song, W., Han, Y., Li, S., & Wu, H. (2026). UHPLC‐Q‐TOF‐MS Identification of Intestinal Absorbable Components of Yindan Pinggan Capsule and Exploration of Its Anti‐NAFLD Mechanism Based on NF‐κB Signaling Regulation. Biomedical Chromatography, 40(12). https://doi.org/10.1002/bmc.70650
Vancouver
Hou J, Zhao J, Yang J, Lai H, Jia M, Song W, et al. UHPLC‐Q‐TOF‐MS Identification of Intestinal Absorbable Components of Yindan Pinggan Capsule and Exploration of Its Anti‐NAFLD Mechanism Based on NF‐κB Signaling Regulation. Biomedical Chromatography. 2026;40(12). doi:10.1002/bmc.70650
BibTeX
@article{Hou2026,
author = {Hou, Jinli and Zhao, Jie and Yang, Jicheng and Lai, Huaqing and Jia, Mengyu and Song, Wenrui and Han, Yutong and Li, Sen and Wu, Hongwei},
title = {UHPLC‐Q‐TOF‐MS Identification of Intestinal Absorbable Components of Yindan Pinggan Capsule and Exploration of Its Anti‐NAFLD Mechanism Based on NF‐κB Signaling Regulation},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {12},
doi = {10.1002/bmc.70650}
}
EUVIMED